Published in J Natl Compr Canc Netw on August 01, 2015
Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. Front Oncol (2016) 0.79
Decreased Mitochondrial Mutagenesis during Transformation of Human Breast Stem Cells into Tumorigenic Cells. Cancer Res (2016) 0.78
Integrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potential. BMC Syst Biol (2015) 0.75
MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol (2013) 112.81
UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem (2004) 112.47
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res (2007) 16.79
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol (2013) 12.57
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med (2011) 12.45
National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. Am Soc Clin Oncol Educ Book (2014) 6.22
Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem (2002) 5.63
Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov (2012) 4.72
Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med (2012) 3.38
Cancer of unknown primary site. N Engl J Med (2014) 3.16
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res (2012) 3.14
Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer (2008) 2.82
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol (2009) 2.71
Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat (2008) 2.65
Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer (2009) 2.60
Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer (2013) 2.56
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol (2013) 2.41
Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res (2005) 1.87
Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw (2014) 1.71
Thyroid transcription factor-1 expression in breast carcinomas. Am J Surg Pathol (2010) 1.65
Breast cancer version 3.2014. J Natl Compr Canc Netw (2014) 1.63
Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J Biol Chem (2011) 1.61
Role of TTF-1, CK20, and CK7 immunohistochemistry for diagnosis of primary and secondary lung adenocarcinoma. Kaohsiung J Med Sci (2006) 1.23
HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res (2011) 1.19
ERBB2 kinase domain mutation in the lung squamous cell carcinoma. Cancer Lett (2005) 1.19
Performance and clinical evaluation of the 92-gene real-time PCR assay for tumor classification. J Mol Diagn (2011) 1.08
Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis. Oncologist (2013) 0.94
New strategies for carcinoma of unknown primary: the role of tissue-of-origin molecular profiling. Clin Cancer Res (2013) 0.91
American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment. J Clin Oncol (2014) 0.90
Occult primary, version 3.2014. J Natl Compr Canc Netw (2014) 0.89
Activating mutations in HER2: neu opportunities and neu challenges. Cancer Discov (2013) 0.86
Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther (2014) 0.80
Is the ``$1000 Genome'' really $1000? Understanding the full benefits and costs of genomic sequencing. Technol Health Care (2015) 0.80